KDR and cancer: The use of small-molecule kinase inhibitors to target key proteins has become an attractive strategy across many cancer types including a number of prospective targeted therapies which have been identified for inhibition of various putative targets in ATC including sorafenib (VEGFR), axitinib (VEGFR), vemurafenib and dabrafenib (BRAF/MEK), imatinib (PDGFR), and selumetinib (MEK 1 and 2) [9].